23 Feb Caribou Biosciences
Rachel Haurwitz, Ph.D., President and CEO
Caribou Biosciences is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging a proprietary technology to develop genome-edited, off-the-shelf CAR T and CAR-NK cell therapies for a range of tumor types. The company’s chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, which enables the performance of multiple, precise genomic edits while maintaining genomic integrity. The company uses its chRDNA technology to enhance its cell therapies by creating genomic edits to improve persistence of antitumor activity, including removing the PD-1 checkpoint in order to reduce premature CAR T cell exhaustion and immune cloaking the cell therapy to prevent rapid rejection by the patient’s immune system.